Loading market information…
ASX · EXL.AX · AUD
Stock price, earnings
Quote as of Oct 29, 2026, 04:47 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Elixinol Wellness Limited’s quoted price sits in the lower half of its reported 52-week range, 72.73% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Elixinol Wellness Limited’s next earnings report is currently expected on Feb 19, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Elixinol Wellness Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Elixinol Wellness Limited, an entity established in 2017 and headquartered in Sydney, Australia, operates internationally through its subsidiaries. The company is primarily involved in the manufacturing and global distribution of a wide array of hemp-derived products, encompassing nutraceuticals, cosmetics, and various food items. These products are marketed under its distinct brands, Elixinol and Hemp Foods Australia, reaching consumers across the Americas, Europe, and Australia. Its extensive product range features hemp-derived cannabidiol (CBD) items, food products, dietary supplements, and topical skincare solutions. Notably, the company transitioned to its current name in May 2021, having previously been known as Elixinol Global Limited.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| A$3.46M-51.47% vs estimate |
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
